NCT02180711 2025-10-15Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaAcerta Pharma BVPhase 1/2 Active not recruiting113 enrolled 19 charts
NCT04836832 2022-06-07Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1 Withdrawn